Showing results (261-270 of 396) with videos related to
Sort By:
Pageof 40
EMBO Molecular Medicine|June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failureMichael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2012
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceChengwen Liu, Weiyi Peng, Chunyu Xu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.JCO Precision Oncology|December 12, 2024
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol VLilian T Gien, Zihe Song, Andrew Poklepovic, et al.Cell|September 12, 2015
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor GrowthSonja Kleffel, Christian Posch, Steven R Barthel, et al.Cancer Discovery|December 28, 2014
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotypeKim H T Paraiso, Meghna Das Thakur, Bin Fang, et al.Pageof 40